Active substance
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| HISTAMINE PHOSPHATE | EQ 1MG BASE/ML; EQ 0.2MG BASE/ML; EQ 0.1MG BASE/ML | injectable · injection | LILLY | Discontinued | 25 Apr 1939 |
Ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (IL-2). The efficacy of Ceplene has not been fully demonstrated in patients older than age 60.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| HISTATROL | 00609692 | 2.75 MG / ML | SOLUTION · PERCUTANEOUS | ALK-ABELLO INC |
| HISTATROL | 00609706 | 0.275 MG / ML | SOLUTION · INTRADERMAL | ALK-ABELLO INC |
| POSITIVE SKIN TEST CONTROL-HISTAMINE | 02439514 | 6 MG / ML | SOLUTION · PERCUTANEOUS | JUBILANT HOLLISTERSTIER LLC |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.